• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing

Does Halozyme Therapeutics, My Q2 Pick, Still Have a HALO Over It?

Let's check the charts on this biotechnology stock and see if it still has a prayer.
By BRUCE KAMICH
Jul 01, 2022 | 01:13 PM EDT
Stocks quotes in this article: HALO

Bitotech Halozyme Therapeutics ( HALO)  was my "top pick" for the second quarter. The quarter has ended, so let's check out the charts to see if this was a worthwhile trade and if we should continue holding HALO. 
 
In this daily bar chart of HALO, below, we can see that prices have managed a move higher the past three months. Compared to the performance of the broad market averages, this recommendation has been a winner, but I am not ready to take a victory lap just yet.
 
Prices are currently testing the rising 50-day moving average line. The 200-day moving average line has turned positive in the past six weeks. The On-Balance-Volume (OBV) line shows a rise from early December. The trend-following Moving Average Convergence Divergence (MACD) oscillator is above the zero-line but needs renewed price strength to turn things more bullish. 
 
 
 
In this weekly Japanese candlestick chart of HALO, below, we find a positive-looking picture. Prices are trading above the rising 40-week moving average line. The weekly OBV line shows strength the past four to five months. I do not see a top reversal pattern nor worrisome upper shadows. The MACD oscillator is bullish, but shows some recent narrowing. 
 

 
 
In this daily Point and Figure chart of HALO, below, we can see an upside price target in the $58 area. 
 
 
 
 
In this weekly Point and Figure chart of HALO, below, we can see that prices have reached an upside price target. A trade at $49.03 should refresh the uptrend and generate a new bullish price target. 
 
 
Bottom line strategy: Overall, the charts and indicators of HALO remain positive. Traders could continue to hold existing longs and consider adding to longs or going long above $49. The $58 area is our price target.
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Technical Analysis | Biotechnology | Life Sciences | Science

More from Investing

This Market Calls for Short-Term Plans

James "Rev Shark" DePorre
Aug 9, 2022 4:44 PM EDT

Looming price data and expected volatility could offer opportunities for very short-term traders, but building longer-term positions is a tougher task.

These 3 ETFs Offer Yield-Hungry Investors Some 'Options'

Mark Abssy
Aug 9, 2022 2:00 PM EDT

As our appetite expands to 'take what we can get' investments, let's look at three funds from Global X and see how they stack up against major index funds.

The World Gets Worse as Inflation Gets Better?

Peter Tchir
Aug 9, 2022 12:50 PM EDT

Here's the shift in the narrative I expect over the coming days.

Bumble, Let's Just Be Friends for Now

Bruce Kamich
Aug 9, 2022 12:29 PM EDT

BMBL has a date with earnings on Wednesday, and the charts say investors should refrain from flirting with the stock.

The Bullish vs. Bearish Narrative on the Market

James "Rev Shark" DePorre
Aug 9, 2022 11:23 AM EDT

The CPI report Wednesday is going to cause a more careful examination of inflation, a hawkish Fed, and a potential recession.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 01:44 PM EDT STEPHEN GUILFOYLE

    This Holding Lights Up With Strong Earnings

    Check out the latest from TheStreet's Stocks Under...
  • 09:24 AM EDT PETER TCHIR

    Jobs Report Reaction: Incredibly Strong, But Questions to Ask

    An incredibly strong July jobs report. Not only d...
  • 08:54 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The Secret to Dealing With FOMO
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login